Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin degludec/insulin aspart - Novo Nordisk

Drug Profile

Insulin degludec/insulin aspart - Novo Nordisk

Alternative Names: DegludecPlus; IDegAsp; Insulin aspart/insulin degludec; Insulin aspart/NN1250; Insulin Degludec/Insulin Aspart 15; NN1045; NN1250/insulin aspart; NN5401; Ryzodeg; SIAC; Soluble insulin analogue combination

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 02 Oct 2018 Efficacy data from the phase III Step by Step trial in Type-2 diabetes mellitus released by Novo Nordisk
  • 31 Jan 2018 Novo Nordisk plans a regulatory post marketing surveillance study for Type 1 and 2 diabetes mellitus in South Korea , (NCT03416855)
  • 24 Dec 2017 Novo Nordisk completes a phase III trial in Type-2 diabetes mellitus in USA, Algeria, Czech Republic, India, Russia, Serbia and Turkey (SC) (NCT02906917)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top